Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors
Cancer is associated with alterations in epigenetic mechanisms such as histone modifications and methylation of DNA, and inhibitors targeting epigenetic mechanisms represent a novel class of anti-cancer drugs. Neuroendocrine tumors (NETs) of the pancreas (PNETs) and bronchus (BNETs), which may have...
Main Authors: | Lines, K, Stevenson, M, Filippakopoulos, P, Müller, S, Lockstone, H, Wright, B, Grozinsky-Glasberg, S, Grossman, A, Knapp, S, Buck, D, Bountra, C, Thakker, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2017
|
Similar Items
-
Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells
by: Lines, KE, et al.
Published: (2020) -
Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches
by: Stevenson, M, et al.
Published: (2018) -
Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs)
by: Grozinsky-Glasberg, S, et al.
Published: (2020) -
The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008) -
Intraductal pancreatic neuroendocrine tumor.
by: Chetty, R, et al.
Published: (2009)